Trial Profile
Phosphatidylinositol 3-kinase (PI3K) Pathway Analysis in Tumor Tissue and Circulating DNA to Obtain Further Insight in the Efficacy of Everolimus When Combined With Exemestane: A Side-study Protocol Attached to Standard Treatment With Everolimus and Exemestane for Postmenopausal Patients With Hormone Receptor-positive Advanced Metastatic Breast Cancer, Who Have Progressed on Anastrozole or Letrozole
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 08 Apr 2022
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Exemestane (Primary)
- Indications Advanced breast cancer
- Focus Biomarker; Pharmacodynamics; Therapeutic Use
- 21 Jun 2020 Results of immunohistochemistry (IHC) analyses in tumour tissue on PI3K/MAPK pathway activation (n=142) published in the Journal of Cancer Research and Clinical Oncology.
- 11 Oct 2019 Planned End Date changed from 1 Jan 2019 to 1 Jan 2021.
- 11 Oct 2019 Planned primary completion date changed from 1 Jan 2019 to 1 Jan 2021.